Real world costs and cost-effectiveness of Rituximab for diffuse large B-cell lymphoma patients: a population-based analysis. [electronic resource]
Producer: 20150420Description: 586 p. digitalISSN:- 1471-2407
- Adolescent
- Adult
- Age Factors
- Aged
- Aged, 80 and over
- Antibodies, Monoclonal, Murine-Derived -- economics
- Antineoplastic Agents -- economics
- Antineoplastic Combined Chemotherapy Protocols -- economics
- Child
- Child, Preschool
- Cost-Benefit Analysis
- Female
- Humans
- Infant
- Lymphoma, Large B-Cell, Diffuse -- drug therapy
- Male
- Middle Aged
- Models, Economic
- Ontario
- Rituximab
- Survival Rate
- Young Adult
No physical items for this record
Publication Type: Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.